RT Journal Article
SR Electronic
T1 Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: A COSMIC study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.20.20106526
DO 10.1101/2020.05.20.20106526
A1 Röhr, Susanne
A1 Pabst, Alexander
A1 Riedel-Heller, Steffi G.
A1 Jessen, Frank
A1 Turana, Yuda
A1 Handajani, Yvonne S.
A1 Brayne, Carol
A1 Matthews, Fiona E.
A1 Stephan, Blossom C.M.
A1 Lipton, Richard B.
A1 Katz, Mindy J.
A1 Wang, Cuiling
A1 Guerchet, Maëlenn
A1 Preux, Pierre-Marie
A1 Mbelesso, Pascal
A1 Ritchie, Karen
A1 Ancelin, Marie-Laure
A1 Carrière, Isabelle
A1 Guaita, Antonio
A1 Davin, Annalisa
A1 Vaccaro, Roberta
A1 Kim, Ki Woong
A1 Han, Ji Won
A1 Suh, Seung Wan
A1 Shahar, Suzana
A1 Din, Normah C.
A1 Vanoh, Divya
A1 Boxtel, Martin van
A1 Köhler, Sebastian
A1 Ganguli, Mary
A1 Jacobsen, Erin P.
A1 Snitz, Beth E.
A1 Anstey, Kaarin J.
A1 Cherbuin, Nicolas
A1 Kumagai, Shuzo
A1 Chen, Sanmei
A1 Narazaki, Kenji
A1 Ng, Tze Pin
A1 Gao, Qi
A1 Gwee, Xin Yi
A1 Brodaty, Henry
A1 Kochan, Nicole A.
A1 Trollor, Julian
A1 Lobo, Antonio
A1 López-Antón, Raúl
A1 Santabárbara, Javier
A1 Crawford, John D.
A1 Lipnicki, Darren M.
A1 Sachdev, Perminder S.
A1 for Cohort Studies of Memory in an International Consortium (COSMIC)
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.20.20106526.abstract
AB Subjective cognitive decline (SCD) is recognized as a risk stage for Alzheimer’s disease (AD) and other dementias, but its prevalence is not well known. We aimed to use uniform criteria to better estimate SCD prevalence across international cohorts. Therefore, we combined individual participant data for 16 cohorts from 15 countries (members of the COSMIC consortium) and used qualitative and quantitative (Item Response Theory/IRT) harmonization techniques to estimate SCD prevalence. The sample comprised 39,387 cognitively unimpaired individuals above age 60. The prevalence of SCD across studies was around one quarter with both qualitative harmonization/QH (23.8%, 95%CI = 23.3%-24.4%) and IRT (25.6%, 95%CI = 25.1%-26.1%); however, prevalence estimates varied largely between studies (QH: 6.1%, 95%CI = 5.1%-7.0%, to 52.7%, 95%CI = 47.4%-58.0%; IRT: 7.8%, 95%%CI = 6.8%-8.9%, to 52.7%, 95%CI = 47.4%-58.0%). Across studies, SCD prevalence was higher in men than women, in lower levels of education, in Asian and Black African people compared to White people, in lower- and middle-income countries compared to high-income countries, and in studies conducted in later decades. Data harmonization and application of uniform criteria across diverse cohorts yielded more accurate estimates of SCD prevalence. Having a quarter of older individuals with SCD warrants further investigation of its significance, as a risk stage for AD and other dementias, and of ways to help individuals with SCD who seek medical advice.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSusanne Rohr was supported by the LIFE—Leipzig Research Center for Civilization Diseases, University of Leipzig, funded by the European Social Fund and the Free State of Saxony (grant number LIFE-103 P1). This work was further supported by a grant from the Hans and Ilse Breuer Foundation. Funding for COSMIC comes from a National Health and Medical Research Council of Australia Program Grant (ID 1093083) (PSS, HB), the National Institute On Aging of the National Institutes of Health under Award Number RF1AG057531 (PSS, MG, RBL, KR, KWK, HB), and philanthropic contributions to The Dementia Momentum Fund (UNSW Project ID PS38235). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funders. Funding for each of the contributing studies is as follows: ActiveAging: no funding; CFAS: major awards from the Medical Research Council and the Department of Health, UK; EAS: Supported in part by National Institutes of Health grants NIA 2 P01 AG03949, the Leonard and Sylvia Marx Foundation, and the Czap Foundation; EPIDEMCA: French National Research Agency (ANR-09-MNPS-009-01); ESPRIT: Novartis; Invece.Ab: Financed with own funds and supported in part by “Federazione Alzheimer Italia”, Milan, Italy (AG); KLOSCAD: the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [Grant No. HI09C1379 (A092077)]; LEILA75+: the Interdisciplinary Centre for Clinical Research at the University of Leipzig (Interdisziplinäres Zentrum für Klinische Forschung/IZKF; grant 01KS9504); LRGS-TUA: Ministry of Education Longterm Research Grant Scheme (LRGS/BU/2012/UKM-UKM/K/01); MAAS: The Netherlands Organization for Scientific Research (NOW). Grant Number: 002.005.019; MoVIES: Grant # R01AG07562 from the National Institute on Aging, National Institutes of Health, United States Department of Health and Human Services; PATH: National Health and Medical Research Council of Australia grants 973302, 179805, 157125 and 1002160; SGS: JSPS KAKENHI Grant Number JP17K09146; SLASII: The SLAS2 study was supported by research grants from the Agency for Science Technology and Research (A*STAR) Biomedical Research Council (BMRC) https://www.a-star.edu.sg/ [Grants 03/1/21/17/214 and 08/1/21/19/567] and the National Medical Research Council http://www.nmrc.gov.sg/ [Grant: NMRC/1108/2007]; ZARADEMP: Supported by grants from the Fondo de Investigation Sanitaria, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness, Madrid, Spain (grants 94/1562, 97/1321E, 98/0103, 01/0255, 03/0815, 06/0617, G03/128), and the Fondo Europeo de Desarrollo Regional (FEDER) of the European Union and Gobierno de Aragón, Group #19.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and material in relation to the manuscript are available for researchers from the corresponding author upon reasonable request.